UNII J2B2A4N98G

LACTOSE, UNSPECIFIED FORM

Unique Ingredient Identifier J2B2A4N98G is listed as a unspecified ingredient
UniiJ2B2A4N98G
Preferred Substance NameLACTOSE, UNSPECIFIED FORM
NcitC28166
Rxcui6211
Unii TypeUNSPECIFIED INGREDIENT
NCITC28166
RXCUI6211

Alternate Names

Dosage Forms

UNII J2B2A4N98G LACTOSE, UNSPECIFIED FORM is commonly included in medications in the following forms.

RouteDosage FormPotency
BUCCALTABLET183.3 MG
BUCCAL/SUBLINGUALTABLET296.7 MG
IM - IVINJECTION20.35 %
IM - IVPOWDER, FOR INJECTION SOLUTION NA
IM - IV - SCINJECTION NA
IM - IV - SCPOWDER, FOR INJECTION SOLUTION13.3 %
INHALATIONCAPSULE20 MG
INHALATIONCAPSULE, HARD GELATIN25 MG
INHALATIONPOWDER9 %
INHALATIONPOWDER, METEREDPOWDER, METERED870 MG/1GM
INTRACAVITARYPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED19.38 %
INTRAMUSCULARINJECTION NA
INTRAMUSCULARPOWDER, FOR INJECTION SOLUTION2 %
INTRAVENOUSINJECTION1 %
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION5 %
IV(INFUSION)POWDER, FOR INJECTION SOLUTION, LYOPHILIZED10 %
IV(INFUSION)SOLUTION, INJECTION0.45 %
ORALCAPSULE530 MG
ORALCAPSULE, COATED PELLETS102.44 MG
ORALCAPSULE, DELAYED ACTION, ENTERIC COATED NA
ORALCAPSULE, ENTERIC COATED PELLETS231.84 MG
ORALCAPSULE, HARD GELATIN100 MG
ORALCAPSULE, SOFT GELATIN115.75 MG
ORALCAPSULE, SUSTAINED ACTION120 MG
ORALCONCENTRATE NA
ORALGRANULE650.75 MG/5ML
ORALGRANULE, FOR SUSPENSION NA
ORALPOWDER, FOR SOLUTION NA
ORALSOLUTION1682 MG/15ML
ORALTABLET2217 MG
ORALTABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE117.7 MG
ORALTABLET, COATED332.05 MG
ORALTABLET, CONTROLLED RELEASE0.017 MG
ORALTABLET, DELAYED ACTION92.02 MG
ORALTABLET, DELAYED ACTION, ENTERIC COATED209 MG
ORALTABLET, DELAYED RELEASE NA
ORALTABLET, EXTENDED RELEASE122.99 MG
ORALTABLET, FILM COATED590 MG
ORALTABLET, MULTILAYER, EXTENDED RELEASE122 MG
ORALTABLET, REPEAT ACTION153.2 MG
ORALTABLET, SUSTAINED ACTION400 MG
ORALTABLET, SUSTAINED ACTION, FILM COATED51.1 MG
ORALTABLET, SUSTAINED RELEASE, FILM COATED38.75 MG
RECTALSOLUTION8 %
RECTALTABLET20 MG
SUBCUTANEOUSPOWDER, FOR INJECTION SOLUTION2 %
SUBCUTANEOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED0.5 %
SUBLINGUALTABLET175.92 MG
TOPICALEMULSION, CREAM NA
TRANSDERMALFILM, CONTROLLED RELEASE675 MG
TRANSDERMALOINTMENT18.9 %
VAGINALEMULSION, CREAM3 %
VAGINALSUPPOSITORY NA
VAGINALTABLET1013 MG

© 2020 FDA.report
This site is not affiliated with or endorsed by the FDA.